Publication | Closed Access

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Patient-reported OutcomesHepatologyMedicineClinical TrialsLenvatinib Versus SorafenibFirst-line TreatmentSurgeryLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaHealth Sciences